Comparative analysis of whole-cell and acellular pertussis vaccines efficacy in preventing pertussis

In light of the increasing incidence of pertussis in many countries much attention is paid to vaccines for immunologic prophylaxis of pertussis. The article dwells upon the use of whole-cell and acellular pertussis vaccines (DTPs and DTaPs, respectively). The analyzed materials demonstrate that the choice of the vaccine (DTP or DTaP) plays a crucial role in the creation of the proportion of the population who are immune to the disease. The wide use of DTPs in 1950s-1960s resulted in more than a 90 % decrease in pertussis incidence and mortality rates. While DTPs are very efficacious they have also been associated with a high degree of reactogenicity (especially those vaccines produced abroad since they contain half or twice as many inactivated pertussis cells as Russian vaccines). An alternative variant is DTaPs which show signficantly lower reactogenicity as compared to DTPs. Available data demonstrate that licensed DTaPs and DTPs have equivalent primary efficacy in preventing the disease during the first year of life, but the effect of APVs is not as long-standing as that of DTPs and this results in a more rapid weakening of the immune system and decrease in the influence on pathogen transmission. Immune protection following the administration of DTaP booster doses decreases more rapidly in those people who received first immunization with a DTaP rather than a DTP. Experts believe that after administration of a repeat DTaP booster dose the weakening of the immunity will be still more rapid. Epidemiological surveillance data suggest that the use of DTaPs can lead to the resurgence of pertussis, and this resurgence may increase the risk of death for children who are too small to be vaccinated. This conclusion is supported by the increase in pertussis incidence in developed countries where the immunological prophylaxis is based on DTaPs only. It is important that specialists make their choice of the prophylactic vaccine based on its effect on the immunity duration and level.

цельноклеточная коклюшная вакцина, бесклеточная коклюшная вакцина, эффективность и безопасность коклюшных вакцин, whole-cell pertussis vaccine, acellular pertussis vaccine, efficacy and safety of pertussis vaccines

1. WHO. Weekly Epidemiological Record. Pertussis vaccines: WHO position paper — August 2015. 2015; 90(35): 433–60.

2. WHO Weekly epidemiological record. Pertussis vaccines: WHO position paper. 2010; 85(40): 385–400.

3. WHO Weekly epidemiological record. Meeting of the Strategic Advisory Group of Experts on Immunization. 2014; 89(21): 221–36.

4. Report from the SAGE Working Group on Pertussis vaccines, 26–27 August 2014 meeting, Geneva, Switzerland. Available from: https://goo.gl/MY4aWo.

5. Edwards KM, Decker MD. Pertussis vaccines. In: Vaccines. 6th ed. Plotkin S, Orenstein W, Offit P., eds. Philadelphia: Saunders, 2013. P. 447–492.

6. Crowcroft NS, Pebody RG. Recent developments in pertussis. Lancet 2006; 367(9526): 1926–36.

7. Préziosi MP, Yam A, Wassilak SG, Chabirand L, Simaga A, Ndiaye M, et al. Epidemiology of pertussis in a West African community before and after introduction of a widespread vaccination program. Am J Epidemiol. 2002; 155(10): 891–6.

8. Laboratory manual for the diagnosis of whooping cough caused by Bordetella pertussis/Bordetella parapertussis. Geneva, World Health Organization, Update 2014 (WHO/IPV/14.03). Available from https://goo.gl/74nuHj.

9. Riffelmann M, Wirsing von König CH, Caro V, Guiso N, for the Pertussis PCR, Consensus Group. Acid amplification tests for diagnosis of Bordetella infections. J Clin Microbiol. 2005; 43: 4925–9.

10. Wirsing von König CH. The immunological basis for immunization series: module 4: pertussis — update 2009. Geneva. World Health Organization, 2010. P. 50.

11. Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, Donegan Ket al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet 2014; 384(9953): 1521–8.

12. WHO expert committee on biological standardization. WHO technical report series, ¹ 941. Annex 6. Recommendations for whole-cell pertussis vaccine. Geneva. World Health Organization. 2007. P. 301–32.

13. Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine 2003; 21: 2003–14.

14. WHO-recommended standards for surveillance of selected vaccine-preventable diseases. Geneva, World Health Organization, 2003 (WHO/V&B/03.01). Available from: http://www.who.int/vaccines-documents/DocsPDF06/843.pdf.

15. Simondon F, Preziosi M, Yam A, Kane CT, Chabirand L, Iteman I et al. A randomized double-blind trial comparing a 2-component acellular to a whole-cellpertussis vaccine in Senegal. Vaccine 1997; 15: 1606–12.

16. Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. BMJ 1988; 296: 612–4.

17. Sheridan SL, Frith K, Snelling TL, Grimwood K, McIntyre PB, Lambert SB. Waning vaccine immunity in teenagers primed with whole cell and acellular pertussis vaccine: recent epidemiology. Exp Rev Vaccines 2014; 13(9): 1081–106.

18. Whole Cell Pertussis Vaccines: Summary of evidence relevant to schedules. Available from: https://goo.gl/8v5z5n; accessed July 2015.

19. WHO Expert Committee on Biological Standardization. Technical Report Series No. 979. Sixty-second report. Annex 4. Recommendations to assure the quality, safety and efficacy of acellular pertussis vaccines. Geneva. World Health Organization. 2013. P. 187–260. https://goo.gl/hRTF4w.

20. Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H. Randomised controlled trial of 2-component, 3-component, and 5-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 1997; 350: 1569–77.

21. Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A et al. A controlled trial of 2 acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. New Engl J Med. 1996; 334: 341–8.

22. Schmitt HJ, von König CH, Neiss A, Bogaerts H, Bock HL, Schulte-Wissermann H et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996; 275(1): 37–41.

23. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a 2-component acellular, a 5-component acellular and a whole-cell pertussis vaccine. New Engl J Med. 1996; 334: 349–55.

24. Zhang L, Prietsch S, Axelsson I, Halperin SA. Acellular vaccines for preventing whooping cough in children. The Cochrane database of systematic reviews. 2014; 9: CD001478.

25. Carlsson R, Trollfors B. Control of pertussis–lessons learnt from a 10-year surveillance programme in Sweden. Vaccine 2009; 27: 5709–18.

26. Okada K, Ohashi Y, Matsuo F, Uno S, Soh M, Nishima S. Effectiveness of an acellular pertussis vaccine in Japanese children during a non-epidemic period: amatched case-control study. Epidemiol Infect. 2009; 137: 124–30.

27. Salmaso S, Mastrantonio P, Tozzi AE, Stefanelli P, Anemona A, Ciofi degli Atti ML et al. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience (Abstract). Pediatrics 2001; 108(5): 1195. Available from: www.pediatrics.org/cgi/content/full/108/5/e81pmid: 11694665.

28. Quinn HE, Snelling TL, Macartney KK, McIntyre PB. Duration of protection after first dose of acellular pertussis vaccine in infants. Pediatrics 2014; 133(3): e513–9.

29. Quinn HE, McIntyre PB. Pertussis epidemiology in Australia over the decade 1995–2005 — trends by region and age group. Communicable Diseases Intelligence 2007; 31: 205–15.

30. CDC. Center for Disease Control and Prevention. CDC 24/7. Available from: https://goo.gl/WNEXrj.

31. WHO SAGE pertussis working group. Background paper. SAGE April 2014. Available from: https://goo.gl/rwaUgq.

32. Warfel JM, Merkel TJ. Reply to Domenech de Celles, et al.: Infection and transmission of pertussis in the baboon model. Proc Natl Acad Sci USA 2014; 111(7): E718.

33. Warfel JM, Merkel TJ. Bordetella pertussis infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates. Mucosal Immunol. 2013; 6(4): 787–96.

34. Hong Choi Y, Campbell H, Amirthalingam G, van Hoek AJ, Miller E. Investigating the pertussis resurgence in England and Wales, and options for future control. BMC Med. 2016; 14: 121.

35. Gambhir M, Clark TA, Cauchemez S, Tartof SY, Swerdlow DL, Ferguson NM. A change in vaccine efficacy and duration of protection explains recent rises in pertussis incidence in the United States (A change in efficacy and duration of pertussis vaccine). PLoS Comput Biol. 2015; 11(4): e1004138.

36. Grading of scientific evidence — table 1: Efficacy/effectiveness of pertussis vaccines in immunocompetent infants and children. Available from: https://goo.gl/SKf6HB.

37. Iozefovich OV, Harit SM, Kaplina SP, Gostiv VV, Sidorenko SV, Kalinogorsky OS et al. Prevalence of pertussis in long-term coughing in children 6–17 years of age, vaccinated at an early age of the DPT vaccine. Epidemiologiya i vaktsinoprofilaktika 2012; (5): 56–9 (in Russian).

38. Onishchenko GG, Ezhlova EB, Melnikova AA. Actual questions of organization of the vaccination in the Russian Federation. Zhurn. mikrobiologii, epidemiologii, immunobiologii 2011; (5): 110–4 (in Russian).

39. Onishchenko GG, Ezhlova EB, Melnikova AA. Current problems of vaccination in the Russian Federation. Zhurn. mikrobiologii, epidemiologii, immunobiologii 2014; (1): 9–19 (in Russian).

40. Alekseevà IA, Chuprynina RP, Borisova VN. A comparative analysis of the safety and efficiency of domestic and foreign integrated vaccines containing whole-cell pertussis vaccine. Epidemiologiya i vaktsinoprofilaktika 2012; (3): 48–54 (in Russian).

41. Alekseevà IA, Chuprynina RP, Perelygina OV, Mironov AN. Harmonization of requirements of pertussis-diphtheria-tetanus vaccine in the project monograph. The vaccine pertussis-diphtheria-tetanus adsorbed. BIOpreparations. Prevention, Diagnosis, Treatment. 2013; (1): 36–40 (in Russian).

42. Prevention and monitoring of post-vaccination complications. Tatochenko VK, Fedorov AM, Ozeretskovsky NA, Eds. Moscow, 2004. 189 p. (in Russian).

43. Nikolaeva AM, Yazykova MN, Kalashnikova EA, Ivanov AV, Speranskaya VN. The study of the safety and antigenic structure of the new acellular pertussis vaccine. Rossiiskii zhurn immunoiogii 2014; 8(3): 914–6 (in Russian).

44. Ozeretskovsky NA, Zatolokina KE, Snegireva I. Suggestions for preventing undesirable reactions at application of immunobiological medicines in Russia. Safety and Risk of Pharmacotherapy. 2015; 1(6): 25–9 (in Russian)